Cognitive deficits found in a pro-inflammatory state are independent of ERK 1/2 signaling in the murine brain hippocampus treated with Shiga toxin 2 from enterohemorrhagic Escherichia Coli by Berdasco, Clara Valentina et al.
1
1 Cognitive deficits found in a pro-inflammatory state are independent of 
2 ERK 1/2 signaling in the murine brain hippocampus treated with Shiga 
3 toxin 2 from enterohemorrhagic Escherichia Coli
4 Clara Berdasco1,2, Alipio Pinto1,2, Mariano Blake3, Fernando Correa4, Nadia A. Longo 
5 Carbajosa5, Patricia Geogeghan6, Adriana Cangelosi6, Mariela M. Gironacci5, Jorge 
6 Goldstein1,2*
7 1 Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos 
8 Aires, Argentina
9 2 Laboratorio de Neurofisiopatología, Instituto de Fisiología y Biofísica “Houssay”, 
10 Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad de Buenos Aires, 
11 Buenos Aires, Argentina
12 3 Instituto de Fisiología y Biofísica “Houssay”, Consejo Nacional de Investigaciones 
13 Científicas y Técnicas, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, 
14 Argentina
15 4 Laboratorio de Fisiopatología de la Preñez y el Parto, Centro de Estudios Farmacológicos 
16 y Botánicos, Consejo Nacional de Investigaciones Científicas y Técnicas, Facultad de 
17 Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
18 5 Departamento de Química Biológica, Instituto de Química y Fisicoquímica Biológicas- 
19 Consejo Nacional de Investigaciones Científicas y Técnicas, Facultad de Farmacia y 
20 Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
.CC-BY 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted August 24, 2020. . https://doi.org/10.1101/2020.08.24.264929doi: bioRxiv preprint 
2
21 6 Centro Nacional de Control de Calidad de Biológicos, Administración Nacional de 
22 Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán", Buenos Aires, Argentina
23  * Corresponding author 
24 E-mail:jogol@fmed.uba.ar ; jorgoldstein@gmail.com (JG)
25 Abstract
26 Shiga toxin 2 (Stx2) from enterohemorrhagic Escherichia coli (EHEC) produces 
27 hemorrhagic colitis, hemolytic uremic syndrome (HUS) and acute encephalopathy. The 
28 mortality rate in HUS increases significantly when the central nervous system (CNS) is 
29 involved. Besides, EHEC also releases lipopolysaccharide (LPS). Many reports have 
30 described cognitive dysfunctions in HUS patients, the hippocampus being one of the brain 
31 areas targeted by EHEC infection. In this context, a translational murine model of 
32 encephalopathy was employed to establish the deleterious effects of Stx2 and the 
33 contribution of LPS in the hippocampus. Results demonstrate that systemic administration 
34 of a sublethal dose of Stx2 reduced memory index and produced depression like behavior, 
35 pro-inflammatory cytokine release and NF-kB activation independent of the ERK 1/2 
36 signaling pathway. On the other hand, LPS activated NF-kB dependent on ERK 1/2 
37 signaling pathway. Cotreatment of Stx2 with LPS aggravated the pathologic state, while 
38 dexamethasone treatment succeeded in preventing behavioral alterations. Our present work 
39 suggests that the use of drugs such as corticosteroids or NF-kB signaling inhibitors may 
40 serve as neuroprotectors from EHEC infection. 
41 Author Summary
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42 Shiga toxin (Stx) from enterohemorrhagic Escherichia coli (EHEC) is one of the most 
43 virulent factors responsible for hemolytic uremic syndrome (HUS). Stx2, the endemic 
44 variant targets the brain, among other organs, thus inducing encephalopathies. Central 
45 nervous system (CNS) compromise was the main predictor of death in patients with HUS. 
46 Stx2 may exert a direct action in the CNS, by disrupting the neurovascular unit. In this 
47 context, we investigate the molecular signaling triggered by Stx2 in the murine brain 
48 hippocampus involved in inflammatory mechanisms that altered hippocampal-related 
49 cognitive behaviors. The present data underscore that the use of drugs such as 
50 dexamethasone or those blocking the cascade by preventing NF-kB translocation to the 
51 nucleus may serve as effective neuroprotectors with potentially beneficial use in the clinic.
52 Introduction
53 Shiga toxin 2 (Stx2) from Shiga toxin producing Escherichia coli (STEC) is one of the 
54 most virulent factors responsible for hemolytic uremic syndrome (HUS), a triad of clinical 
55 events that includes acute renal failure, nonimmune microangiopathic hemolytic anemia 
56 and thrombocytopenia. Prodromal bloody diarrhea may occur due to infection with 
57 diarrheagenic Escherichia coli pathotypes, mainly the serotype O157: H7 of 
58 enterohemorrhagic Escherichia coli (EHEC) [1-3]. 
59 The highest rates of HUS on the planet (more than 400 annual cases) are found in 
60 Argentina, where the incidence of pediatric cases reaches up to 17 cases per 100,000 
61 children under 5 years of age [4]. The lethality reported in these patients is between 1 to 4% 
62 but it may rise up to 3-fold when the central nervous system (CNS) is involved [5-7]. 
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63 Acute encephalopathy produced by STEC infection represents a critical episode in severe 
64 cases of disease [8]. We and other laboratories have demonstrated that Stx2 may exert a 
65 direct action in the CNS, in neurons and glial cells [9-12]. Furthermore, it has been reported 
66 that STEC may affect the CNS without renal involvement [13].  
67 Stx2 produces its deleterious action through its canonical cell membrane receptor 
68 globotriaosylceramide (Gb3), a glycosphingolipid localized on the external bilayer lipid 
69 cell membrane. Once Stx2 binds to Gb3, the toxin reaches the ribosomes through a 
70 retrograde pathway and triggers ribotoxic stress leading to pro-apoptotic and pro-
71 inflammatory mechanisms [14]. In addition to Stx2, the Gram-negative STEC also releases 
72 lipopolysaccharide (LPS), an endotoxin derived from its outer membrane [15]. It has been 
73 reported that patients with HUS/encephalopathy also present endotoxemia. Several animal 
74 models developed to study the effect of endotoxemia on STEC pathogenesis have shown 
75 that LPS amplifies the deleterious effects of STEC. In connection with this amplification, 
76 we have previously reported a relevant pro-inflammatory component in CNS damage 
77 produced by Stx2 [10, 11, 16].
78 Several reports have described cognitive dysfunction in HUS patients, the hippocampus 
79 being one of these damaged areas in the brain [17-20]. Alterations found in these patients 
80 include trouble finding words, severe alteration of consciousness, late memory decline, 
81 orientation deficits, seizures and coma. We have previously demonstrated morphological 
82 alterations induced by Stx2 and/or Stx2+LPS in the murine hippocampus [11]. In this 
83 regard, the aim of this work was to dig deeper in the understanding of the alterations 
84 mentioned above, which produce a cognitive decrease in memory and depression-like 
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85 behavior related to hippocampal damage. Furthermore, we sought to establish whether pro-
86 inflammatory involvement played a relevant role in pathogenesis and elucidate the 
87 intracellular mechanism likely to be involved in these events.
88 Materials and Methods
89 Animals
90 NIH male Swiss mice of 4 weeks (approximately 25±3 g) were housed under 12 h-light/12 
91 h-dark cycles. Food and water were provided ad libitum and the experimental protocols and 
92 euthanasia procedures were reviewed and approved by the Institutional Animal Care and 
93 Use Committee of the School of Medicine, Universidad de Buenos Aires, Argentina 
94 (Resolution Nº 046/2017). After an acclimatization period, animals were divided into four 
95 different groups according to intravenous (i.v.) treatment (the total amount of i.v. solution 
96 injected was 100 µl per mouse): Control (saline solution), LPS (800 ng), Stx2 (1 ng) and 
97 Stx2+LPS (1 ng and 800 ng, respectively). Stx2 dose was about 60% of the LD50 (1.6 ng 
98 per mouse). All the procedures were performed in accordance with the EEC guidelines for 
99 the care and use of experimental animals (EEC Council 86/609).
100 Nose-poke habituation task
101 The apparatus employed was a hole-board (Ugo Basile Mod. 6650, Comerio, Italy) made of 
102 a matte gray Perspex panel (40 cm× 40 cm× 22 cm) which has 16 flush mounted tubes of 3 
103 cm (Figure 1A). Each tube has an infrared emitter and a diametrically opposed receiver 
104 connected to an automatic counter to register the number of nose-pokes into the holes. The 
105 assay consisted of two stages: training (TR) and retention test (TS). TR was performed 2 
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106 days after the i.v. treatment. During TR, each mouse was placed at the center of the 
107 apparatus and the number of nose-pokes was automatically registered for 5 minutes (Fig 
108 1A). During the TS stage, performed 30 minutes after TR, each mouse was placed again on 
109 the apparatus and the nose-pokes were registered for 5 minutes. The apparatus was 
110 carefully cleaned with ethanol 70% to avoid interference by previous animals’ 
111 performance. Exploratory activity was expressed as nose-pokes per 5 minutes. Differences 
112 in the number of nose-pokes between TR and TS represent the development of memory. A 
113 more significant difference between TR and TS means better memory formation. Results 
114 were also represented using a memory index derived from the following mathematical 
115 formula: 
116 Memory Index =
(number of training visits ― number of test visits)
number of training visits
117 Immunofluorescence assay
118 Two days after the i.v. treatments mice were anesthetized with sodium pentobarbital (100 
119 mg/kg) and intracardiacally perfused with paraformaldehyde 4% diluted in 0.1 M 
120 phosphate buffer saline (PBS), pH 7.4. The brains were removed from the skulls, post-fixed 
121 overnight at 4 °C with the same fixative solution described above, cryopreserved daily with 
122 solutions with increasing concentrations of sucrose in PBS (10, 20 and 30%), and left 
123 overnight at 4 °C. Brain sections of 20 µm were obtained in a cryostat and stored at -20°C 
124 in a cryopreservation solution (50% PBS, 30% ethylene glycol and 20% glycerol) until the 
125 day of the immunofluorescence assay.
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126 Immunofluorescence for ionized calcium binding adaptor molecule 1 (Iba1) was carried out 
127 to evaluate microglia (MG) reactivity. For this purpose, brain sections were blocked with a 
128 PBS solution containing 0.1% Triton X-100 and 10% goat serum to be incubated with a 
129 monoclonal goat anti-Iba1 antibody overnight at 4 °C (1:250 - Millipore, Temecula, CA, 
130 USA) followed by a donkey anti-goat Alexa Fluor 488 antibody (1:500 - Millipore, 
131 Temecula, CA, USA) for one hour at room temperature. All brain sections were also 
132 incubated with Hoechst 33342 (1:500 - Sigma, St. Louis, MO, USA) for 15 minutes at 
133 room temperature to detect brain cell nuclei. Negative controls were carried out by omitting 
134 the primary antibody. The hippocampal CA1 area (-1.70 and -1.82mm from bregma) was 
135 observed on an Olympus BX50 epifluorescence microscope equipped with a Cool-Snap 
136 digital camera and on an Olympus FV1000 confocal microscope.
137 Four distinct MG phenotypes immunolocalized in the hippocampal CA1 area were 
138 classified according to morphology [21]: ramified, hyper-ramified, bushy, and ameboid. A 
139 ramified morphology is associated with a resting microglial profile and was identified as a 
140 small soma with multiple long thin processes. The hyper-ramified phenotype was identified 
141 as a larger soma with thicker and branching processes. Bushy MG were also identified as 
142 having a larger soma with thicker but fewer processes. The ameboid morphology was 
143 identified as the largest soma with very few or absence of processes. The proportion of each 
144 type of morphology was measured for each treatment. Microglial activation was quantified 
145 using the following formula [22]:  
146 Microglial activation score = (0 x n) + (1 x n) + (2 x n) + (3 x n)
147 The numbers 0, 1, 2 and 3 represent arbitrary factors for the four different microglial 
148 morphologies (ramified=0, hyper-ramified=1, bushy=2, and amoeboid=3), and “n” 
.CC-BY 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted August 24, 2020. . https://doi.org/10.1101/2020.08.24.264929doi: bioRxiv preprint 
8
149 represents the number of microglial cells with each specific morphology and corresponding 
150 arbitrary factor per micrograph.
151 Enzyme-linked immunosorbent assay (ELISA)
152 Animals were sacrificed by decapitation 1 or 2 days after the four i.v. treatments, and the 
153 hippocampi were dissected and then homogenized on ice in PBS containing protease 
154 inhibitor cocktail (Sigma, St. Louis, MO, USA). Next, samples were centrifuged at 10,000 
155 g for 15 minutes at 4 °C. IL-6, TNFα and IL-10 concentrations were immediately 
156 determined in the supernatant of murine hippocampal homogenates using the specific 
157 ELISA with antibodies and standards obtained from BD Biosciences (San Diego, CA, 
158 USA). The assay was performed according to the manufacturers’ instructions.
159 Western blot
160 Animals were sacrificed by decapitation 2, 6, 12 and 24 hours after the i.v. treatments, and 
161 the hippocampi were dissected and homogenized in ice-cold lysis buffer (pH 7.4) 
162 containing 24 mmol/L HEPES, 1 mmol/L EDTA, 2 mmol/L tetrasodium pyrophosphate, 70 
163 mmol/L sodium fluoride, 1 mmol/L β-glycerophosphate, 1% Triton X-100, 1 mmol/L 
164 PMSF, 10 μg/ml aprotinin and 2 μg/ml leupeptin (Sigma, St. Louis, MO, USA). Protein 
165 concentration in the homogenates was quantitatively determined through the Bradford 
166 assay. Hippocampal samples with equal amounts of protein (40 µg) were separated by 
167 electrophoresis in 10% sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) and 
168 transferred onto PVDF membrane (Bio-Rad Labs Inc.). Nonspecific binding sites on the 
169 membrane were blocked by incubation with 5% milk in Tris-buffered saline solution 
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170 containing 0.1% Tween 20 at room temperature for 1 hour. The membranes were then 
171 incubated with primaries antibodies (1:500) overnight at 4 °C: rabbit anti-pERK1/2, rabbit 
172 anti-ERK1/2, rabbit anti-pIĸBα or rabbit anti-IĸBα. To avoid inaccuracies in protein 
173 loading, mouse anti-GAPDH was employed as an internal standard. All primary antibodies 
174 were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). After 1-hour 
175 rinse, membranes were incubated with horseradish peroxidase-conjugated secondary 
176 antibody at 37 °C for 1 hour. Protein loading was evaluated by stripping and reblotting 
177 membranes with anti-GAPDH antibody (1:1000).
178 Forced swim test
179 The four i.v. treated mouse groups described in Animals received either saline solution 
180 (without dexamethasone) or dexamethasone (7.5 mg/kg) by intraperitoneal (i.p. 100 µl) 
181 administration once a day for two consecutive days. Day zero was considered the day of the 
182 i.v. and i.p. treatments. Thus, the eight groups were divided as follows: Control with or 
183 without dexamethasone, LPS with or without dexamethasone, Stx2 with or without 
184 dexamethasone and Stx2+LPS with or without dexamethasone. After two days of 
185 treatments, each mouse was placed for 6 minutes in 3-liter beakers containing a volume of 
186 water at 25 °C that measured 15 cm height, which prevented mice from reaching the 
187 bottom of the container.  The 6-minute test was recorded, and the time of immobility was 
188 measured only in the last 4 minutes [23]. After this time, each mouse was removed from the 
189 container and placed temporarily in a drying cage with a heat lamp above it. The water was 
190 changed after every session to avoid influence on the next mouse.
191 Statistical analysis
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192 All experimental data are presented as the mean ± SEM. Particularly, in the forced swim 
193 test, statistical significance was evaluated using two-way analysis of variance (ANOVA). 
194 For all other assays, statistical significance was evaluated using one-way ANOVA followed 
195 by Bonferroni’s post hoc test (GraphPad Prism 4, GraphPad Software Inc., San Diego, CA, 
196 USA). The criterion for significance was p<0.05 for all experiments. 
197 Results
198 Stx2+LPS reduced short term memory 
199 The nose-poke habituation task was employed to establish whether the toxins change the 
200 capability of mice to store and evoke short term memories [24]. While no significant 
201 differences were found in exploratory activity among groups during TR (Control, LPS, 
202 Stx2 and Stx2+LPS), mice treated with Control, LPS or Stx2 yielded a significant reduction 
203 in the number of nose-pokes recorded between TR and TS (Fig 1B). These findings suggest 
204 that mice in these groups were able to store and retrieve short-term memory of the 
205 habituation task. Nevertheless, no significant differences were found between TR and TS 
206 for Stx2+LPS-treated mice, which is indicative of amnesia. Consequently, the memory 
207 index was significantly lower in Stx2+LPS-treated mice compared to all other treatments 
208 (Fig 1C) (p<0.05). No differences were observed in the memory index across Control, LPS 
209 and Stx2-treated mice.
210 Toxins produced MG reactivity in the CA1 hippocampal area
211 Iba1 is a microglial/macrophagic-specific calcium-binding protein which participates in 
212 membrane ruffling and phagocytosis in activated microglia [25]. An anti-Iba1 antibody was 
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213 employed to establish whether the toxins produced activated MG morphology, as this 
214 molecule is upregulated in activated MG states [21, 22, 26].
215 After 2 days of treatment, the four MG morphological types were observed in the CA1 
216 hippocampal area (Fig 2A). The MG activation score was significantly increased by both 
217 toxins compared to Control (Fig 2B), and maximally increased in Stx2+LPS-treated mice. 
218 No significant differences were found between LPS and Stx2-treated mice. In addition, the 
219 toxins also produced a significant increase in hyper-ramified, bushy and amoeboid MG 
220 activated morphologies as compared to Control (Fig 2C). In contrast, the toxins produced a 
221 significant decrease in ramified morphology (Fig 2C).
222 Toxins increased pro-inflammatory cytokines and decreased anti-inflammatory 
223 cytokines in the hippocampus 
224 In order to establish whether these toxins altered the pro-inflammatory and anti-
225 inflammatory cytokine profile in the mouse hippocampus treated with LPS and/or Stx2, an 
226 ELISA was performed to measure pro-inflammatory cytokines IL-6 and TNFα and anti-
227 inflammatory cytokine IL-10. The expressions of IL-6 and TNFα were both significantly 
228 increased after 1 day of treatment in all toxin-treated mice (Fig 3A, B). On the other hand, 
229 IL-10 was significantly decreased after 1 day of treatment only in Stx2+LPS-treated mice 
230 (Fig 3C), but significantly decreased after 2 days of treatment in all toxin-treated mice (Fig 
231 3D).
232 The pro-inflammatory profile induced by Stx2 was pIkB-dependent but ERK-
233 independent
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234 Given that toxins induced the expression of pro-inflammatory cytokines, we next studied 
235 the intracellular signaling involved in these processes. For this purpose, the ERK and IkB 
236 phosphorylation profiles were determined by Western blot following treatment with 
237 Stx2+LPS between 2 and 24 hours. As shown in figure 4A, upper panel, a significant 
238 reduction in phosphorylated ERK (pERK) was observed after 12 hours of treatment, while 
239 pIkB was increased after 2 hours (Fig 4B, upper panel).
240 To investigate whether the response elicited by Stx2+LPS may be due to a synergistic 
241 effect of both compounds, we evaluated the individual effect of LPS or Stx2 on ERK and 
242 IkB phosphorylation. After 12 hours, Stx2 but not LPS alone induced a decrease in ERK 
243 phosphorylation (Fig 4A, lower panel), which suggests that the reduction in ERK activation 
244 induced by Stx2+LPS resulted from a predominant effect of Stx2. Regarding Ikb, 2 hours 
245 of treatment with Stx2 or LPS alone induced the same increase in IkB phosphorylation as 
246 combined Stx2+LPS treatment (Fig 4B, lower panel).
247 Stx2 and Stx2+LPS induced depression-like behavior, which was attenuated by 
248 dexamethasone 
249 To evaluate whether the toxins produced depression-like behavior and whether this 
250 behavior may involve an inflammatory component, toxin-treated mice were treated with 
251 corticosteroid dexamethasone and then subjected to the forced swimming test. Immobility 
252 time (considered when the animals were restricted to floating movements [23] was 
253 significantly higher in Stx2+LPS-treated mice as compared to Stx2, and also significantly 
254 increased in these two groups compared to LPS and Control (Fig 5). Treatment with 
255 dexamethasone significantly reduced immobility time in Stx2 and Stx2+LPS-treated mice 
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256 (Fig 5). No significant differences were found between the i.p. treatments in Control and 
257 LPS-treated mice.       
258 Discussion
259 In vivo studies and clinical reports have shown the importance of neuroinflammation in the 
260 pathogenesis of Stx2-induced encephalopathy [10, 16, 27, 28]. However, none of these 
261 studies have shown the molecular pathways through which the inflammation is produced. 
262 The current report presents for the first time an introduction to the molecular mechanisms 
263 triggered by Stx2 in the murine brain hippocampus. Furthermore, it connects the 
264 inflammatory process triggered by Stx2 at the molecular level with behavioral changes, 
265 which confirms our previous results showing damage in the neurovascular unit produced by 
266 Stx2 in the CA1 hippocampal area [11].
267 The alterations in memory index and depression-like behavior produced by the toxins in the 
268 nose-poke habituation task and the forced swimming test, respectively, may be related with 
269 damage in hippocampal neurons and correlate with the cognitive imbalance reported in 
270 patients [17]. Considering previous reports [9-11], Stx2 may damage hippocampal neurons 
271 in at least two ways: first, Stx2 binds to the canonical Gb3 receptor localized in CA1 
272 hippocampal neurons; and, second, indirectly by an inflammatory process with MG playing 
273 a fundamental role [10]. Indeed, we have recently reported in an in vitro model that Stx2 is 
274 up-taken by MG through its receptor Gb3, which produces an increase in MG metabolism, 
275 phagocytic capacity and  pro-inflammatory cytokine release [29]. 
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276 MG are mononuclear phagocytes resident in CNS parenchyma. MG are important sentinels 
277 responsible for CNS homeostasis which play an important role in synaptic organization, 
278 control of neuronal excitability, phagocytic removal of debris and trophic support leading 
279 to brain protection and repair [30, 31]. As primary innate immune cells, MG actively move 
280 through the CNS microenvironment while they sense disturbances in homeostasis by 
281 extending and retracting their fine processes [31]. Once they find some homeostatic 
282 imbalance through their wide range of receptors, MG change their morphology from a 
283 highly ramified small cell soma (traditionally called “resting”) to a variety of other distinct 
284 morphologies (traditionally called “activated”), ultimately becoming a poorly ramified 
285 amoeboid cell soma. These cells are also highly specialized in cytokine secretion [21, 22].
286 Stx2 and LPS produced a significant increase in the secretory MG morphology, with more 
287 amoeboid than ramified cells. Furthermore, this event was accompanied by a significant 
288 increase in pro-inflammatory IL-6 and TNFα and a significant reduction in anti-
289 inflammatory IL-10 secretory profile. Traditionally, cytokine secretion has been classified 
290 according to its pro or anti-inflammatory profile. The M1 profile is responsible for the 
291 secretion of pro-inflammatory cytokines like IL-6 and TNFα. In contrast, the M2 profile is 
292 responsible for the secretion of anti-inflammatory cytokines such as IL-10 [32-34]. In 
293 addition, secretory ameboid MG morphology may also be an important oxidative source of 
294 reactive oxygen species (ROS) and nitric oxide (NO) radical derived products [35], as we 
295 have previously shown in the current model of Stx2-produced encephalopathy [11]. 
296 Cytokine synthesis is regulated by many intracellular signaling pathways triggered by 
297 different kinds of receptors that respond to different stimuli [36, 37]. For example, the 
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298 binding of LPS to toll-like receptor 4 (TLR4) leads to the activation of the intracellular 
299 mitogen-activated protein kinase (MAPK) pathway and NF-κB nuclear translocation, 
300 which results in the secretion of pro-inflammatory cytokines [38, 39]. However, 
301 information regarding the intracellular signaling pathway triggered by Stx2 is very scarce, 
302 and particularly much less is known about it in brain parenchymal cells.
303 To our knowledge, all that is known so far about damage produced by Stx via the MAPK 
304 pathway is the activation of p38, which induces IL-8 secretion in the human colonic 
305 epithelial cell line [40], IL-1 secretion by human macrophages [41] and TNF production by 
306 a human adenocarcinoma-derived renal tubular epithelial cell line [42]. In addition, p38 
307 activation has been also found partially responsible for Stx-induced cell death in Vero cells 
308 [43] and in intestinal epithelial cells [44]. On the other hand, the inhibition of p38 is a 
309 determinant of TNF up-regulation from Stx toxicity in brain microvascular endothelial cells 
310 [45]. Furthermore, signaling cascades including JNK and p38 molecules have been related 
311 to cell death by ribotoxic stress leading to apoptosis in intestinal epithelial cells [44]. 
312 MAPKs are a family of proteins which, in response to the activation of cell surface 
313 receptors, phosphorylate specific serine or threonine residues preceded by a proline residue 
314 on their substrates. Extracellular signals such as hormones, cytokines or growth factors 
315 activate the MAPK cascade which consists in a linear signaling triad comprising a MAPK 
316 kinase kinase (MAPKKK or MAP3K) and a MAPK kinase (MAPKK or MAP2K), ending 
317 in the phosphorylation and activation of MAPKs, which include the extracellular signal 
318 regulated kinases 1 and 2 (ERK1/2), p38 isoforms (α, β, γ, and δ) and c-Jun N-terminal 
319 kinases (JNK1, JNK2, and JNK3). The activation of MAPKs culminates with the 
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320 phosphorylation of many cytosolic and nuclear substrates such as downstream kinases, 
321 phosphatases or transcription factors. The dysregulation of this intracellular cascade is 
322 implicated in many neurological disorders, including depression and Alzheimer’s disease 
323 [46]. Similar dysregulation was also found in our present work and could be compared to 
324 these neurological disorders.
325 According to the present data, in our encephalopathy murine model, the deleterious effect 
326 produced by Stx2 together with LPS [10, 11, 16, 29] suggests a potentially synergistic 
327 action rather than an additive one (Fig 6). While both toxins induced the activation and 
328 translocation of NF-κB to the nucleus, they performed it independently through two distinct 
329 pathways: LPS activated the ERK1/2 pathway, and Stx2 activated an ERK1/2-independent 
330 pathway. Furthermore, both pathways also produced the expression of genes related to a 
331 pro-inflammatory state such as TNFα and IL-6 and reduced the expression of those 
332 associated to anti-inflammatory cytokines such IL-10. Although further experiments are 
333 necessary to determine whether p38, JNK or a third unknown pathway may be regulated by 
334 Stx2 concerning NF-κB activation, it may be concluded that the activation of these 
335 molecular cascades may also be implicated in the activation of MG and concomitant 
336 cognitive deterioration observed in the current mouse model. Moreover, the fact that this 
337 deterioration has also been reported in patients suggests that the intracellular mechanisms 
338 studied in this work may also be at play in clinical scenarios. Since there is no consensus 
339 therapy currently available to treat STEC-derived encephalopathy, it is essential to 
340 elucidate the molecular mechanisms underlying the pathophysiological process of 
341 encephalopathy produced by Stx2 to propose therapeutic strategies which may efficiently 
342 protect the brain parenchyma [47]. Accordingly, our present work shows that the use of 
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343 drugs such as dexamethasone or those blocking the cascade by preventing NF-kB 
344 translocation to the nucleus may serve as effective neuroprotectors with potentially 
345 beneficial use in the clinic. 
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465 Figure 1. Short term memory. A: the hole-board apparatus (left), representative nose-
466 poke assay (right). B and C: tests measured after 2 days of treatment. TR: training test; TS: 
467 retention test. Different letters (a, b) represent significant differences. Data were analyzed 
468 by non-parametric one-way ANOVA, Bonferroni's post hoc test, p<0.05, n=15.
469
470 Figure 2. CA1 hippocampal MG response to toxins. A: Iba1 immunofluorescence of 
471 representative images from all distinct morphological MG types. B: microglial activation 
472 score after 2 days of treatment. Each letter (a, b, c) represents significant differences across 
473 each treatment. C: percentage of the microglial morphology in each treatment. Asterisks (*) 
474 represent significant differences across morphologies from all toxin-treated mice as 
475 compared to Control. Data from figures B and C were analyzed by one-way ANOVA, 
476 Bonferroni's post hoc test, p<0.05, n=4.
477
478 Figure 3. Pro- and anti-inflammatory cytokine measurements in the murine 
479 hippocampus. A: IL-6 after 1 day of treatment. B: TNFα after 1 day of treatment. C: IL-10 
480 after 1 day of treatment. D: IL-10 after 2 days of treatment. Each letter (a, b) represents 
481 significant differences across treatments in all figures. Data were analyzed by one-way 
482 ANOVA, Bonferroni's post hoc test, p<0.05, n=8.
483
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484 Figure 4. Changes in intracellular signaling. A, upper panel: Western blot of pERK 1/2 
485 expression after 2, 6, 12 and 24 hours of Control or Stx2+LPS treatments; A, lower panel: 
486 Western blot of pERK 1/2 after 12 hours of the four treatments. B, upper panel: Western 
487 blot of pIĸBα after 2, 6, 12 and 24 hours of Control or Stx2+LPS treatments; B, lower 
488 panel: Western blot of pIĸBα after 2 hours of the four treatments. Each letter (a, b and c) 
489 represents significant differences across treatments. All data were analyzed by one-way 
490 ANOVA, Bonferroni´s post hoc test, p<0.05, n=8.
491 Figure 5. Depression-like behavior and the effects of dexamethasone. The effect of 
492 toxins and dexamethasone on mouse behavior after 2 days of treatment. Each letter (a, b) 
493 represents significant differences between i.p. treatments with or without dexamethasone. *1 
494 represents a significant difference between Stx2-treated mice without dexamethasone and 
495 the other treated mice without dexamethasone. *2 represents significant differences between 
496 Stx2+LPS-treated mice without dexamethasone and the other treated mice without 
497 dexamethasone.  Data were analyzed by non-parametric two-way ANOVA, Bonferroni's 
498 post hoc test, p<0.05, n=12. 
499 Figure 6: Suggested model of Stx2 and LPS intracellular deleterious actions in the 
500 murine hippocampus: The toxins reach the hippocampus crossing the blood-brain barrier 
501 that activate microglial cells. They activate NF-κB translocation to the nucleus through two 
502 distinct pathways engaging inflammatory processes and cognitive deficits. Astrocyte 
503 (green); MG cells (violet); neuron (yellow). 
504
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